Videos

Steven Lucio of Novation discusses how Teva's Granix (tbo-filgrastim), which was filed through a 351(a) pathway, was approved for only 1 indication--and it was not the indication considered to be the "most definitive" for that particular product.

Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.

Manufacturing patents will play a larger role than molecule patents within the biologics development process, and these will also be a factor in terms of bringing complex products to market, argued Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.

Last year there were 11 new cancer drugs approved, and so far this year, 6 oncology medications have been approved, notes Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.

The process of adding biosimilars to formularies will be much more rigorous than what the industry is accustomed to seeing in the generic molecule space, asserted Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.

David G. Miller, RPh, discusses concerns regarding the regulatory status of compounding medications for office use by physicians or dentists.

We will see a new wave of oral antiviral hepatitis C medicines hitting the market towards the end of this year and the beginning of next year, noted Aimee Tharaldson, PharmD, senior clinical consultant, Emerging Therapeutics, Express Scripts.

Stephan Foster, PharmD, FAPha, explains why pharmacists are providing an increasing portion of vaccinations.

David G. Miller, RPh, discusses H.R. 3204, the Drug Quality and Security Act, which passed the House of Representatives on September 25, 2013.

Steven Lucio of Novation discusses why now is the time for pharmacists to educate themselves about biosimilars and the complexities surrounding biologic manufacturing.

Mitchell Katz, PhD, executive director, medical research operations at Purdue Pharma L.P., explains the function of a Contract Research Organization (CRO) and its role in drug development.

Jonathan G. Marquess, PharmD, CDE, explains why he decided to focus on caring for diabetes patients at his pharmacy.

Robert Granko, PharmD, MBA, discusses how his hospital system developed a model that used data to determine how pharmacists should be positioned.

Leigh Ann Bruhn, director of Avalere Health, notes that limited distribution for specialty pharmaceuticals can improve a manufacturer's data capture capabilities.

Joe Moose, PharmD, discusses what it means to shift from a volume-driven business to a value-driven business.

Edmund Pezalla, MD, MPH, national medical director, pharmacy policy and strategy at Aetna, explains how drugs that have been deemed "failures" can sometimes become effective treatments for other conditions.

Pharmacy Times Health-System Edition Editor Stephen F. Eckel, PharmD, MHA, describes his most rewarding experiences working with pharmacy students.

In this video, Todd Speranzo of Avella talks about how to create video content that is compelling to patients.

Stephan Foster, PharmD, FAPha, discusses the history of preventive medicine in the the pharmacy.

Robert Granko, PharmD, MBA, discusses the move to use business intelligence and data analytics in health systems to better understand what is driving cost increases.

In this video from the 2013 Armada Specialty Pharmacy Summit, Mark Zitter of Zitter Health Insights discusses stakeholder views on copay cards.

Pharmacy Times Health-System Edition Editor Stephen F. Eckel offers advice to pharmacy students who are considering a career in health-system pharmacy.

David G. Miller, RPh, discusses the roles of the FDA and state boards of pharmacy in regulating compounding pharmacies.

A patient who thought chronic pain meant she would never work again or have a normal family life found relief at the Nebraska Medical Center.

David G. Miller, RPh, discusses whether and how regulation of compounding pharmacies needs to change.

Specialty Pharmacy Times contributor Quintin Jessee discusses why he chose a career in specialty pharmacy and the new opportunities that are emerging in this industry.

A patient with unyielding pain for a decade learns how to manage her pain at the Mayo Clinic's Pain Rehabilitation Center.

Sherilyn Driscoll, MD, a pediatrics physiatrist at the Mayo Clinic, discusses how treatment of chronic pain in children has changed.

Mark Zitter, CEO at Zitter Health Insights, explains how the growth of Accountable Care Organizations may impact specialty drug management in the near future.

Bill Sullivan of the Specialty Pharmacy Association of America describes the growth of the specialty pharmacy industry and the factors that prompted the formation of SPAARx.